Literature DB >> 16127074

In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.

Jennifer L Hammond1, Urvi M Parikh, Dianna L Koontz, Susan Schlueter-Wirtz, Chung K Chu, Hengameh Z Bazmi, Raymond F Schinazi, John W Mellors.   

Abstract

Serial passage of human immunodeficiency virus type 1 in MT-2 cells in increasing concentrations of the d- and l-enantiomers of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (d4FC) resulted in the selection of viral variants with reverse transcriptase substitutions M184I or M184V for l-d4FC and I63L, K65R, K70N, K70E, or R172K for d-d4FC. Phenotypic analysis of site-directed mutants defined the role of these mutations in reducing susceptibility to l- or d-d4FC.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127074      PMCID： PMC1195387          DOI： 10.1128/AAC.49.9.3930-3932.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses.

Authors:  T L Kinjerski; R W Buckheit
Journal:  Antiviral Res       Date:  1997-01       Impact factor: 5.970

2.  In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

Authors:  Urvi M Parikh; Dianna L Koontz; Chung K Chu; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.

Authors:  J P Kleim; I Winkler; M Rösner; R Kirsch; H Rübsamen-Waigmann; A Paessens; G Riess
Journal:  Virology       Date:  1997-04-28       Impact factor: 3.616

4.  In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.

Authors:  H Z Bazmi; J L Hammond; S C Cavalcanti; C K Chu; R F Schinazi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Adviye A Tolun; Ingrid Pfeifer; Antero G So; John W Mellors; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.

Authors:  Raymond F Schinazi; John Mellors; Holly Bazmi; Sharon Diamond; Sena Garber; Karen Gallagher; Romas Geleziunas; Ron Klabe; Michael Pierce; Marlene Rayner; Jing-Tao Wu; Hangchun Zhang; Jennifer Hammond; Lee Bacheler; Douglas J Manion; Michael J Otto; Lieven Stuyver; George Trainor; Dennis C Liotta; Susan Erickson-Viitanen
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors:  J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

8.  Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro.

Authors:  T S Lin; M Z Luo; M C Liu; Y L Zhu; E Gullen; G E Dutschman; Y C Cheng
Journal:  J Med Chem       Date:  1996-04-26       Impact factor: 7.446

9.  HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

Authors:  Romas Geleziunas; Karen Gallagher; Hangchun Zhang; Lee Bacheler; Sena Garber; Jing-Tao Wu; Guoen Shi; Michael J Otto; Raymond F Schinazi; Susan Erickson-Viitanen
Journal:  Antivir Chem Chemother       Date:  2003-01

Review 10.  Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase.

Authors:  Adrian S Ray; Raymond F Schinazi; Eisuke Murakami; Aravind Basavapathruni; Junxing Shi; Suzana M Zorca; Chung K Chu; Karen S Anderson
Journal:  Antivir Chem Chemother       Date:  2003-05
View more
  10 in total

1.  HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Authors:  Atsuko Hachiya; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Xiongying Tu; Krzysztof Palczewski; Yee Tsuey Ong; Zhe Li; Daniel T Griffin; Matthew M Schuckmann; Junko Tanuma; Shinichi Oka; Kamalendra Singh; Eiichi N Kodama; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2012-07-02       Impact factor: 5.157

2.  Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  D Bradshaw; S Malik; C Booth; M Van Houtte; T Pattery; A Waters; J Ainsworth; A M Geretti
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

3.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase.

Authors:  Raymond F Schinazi; Ivana Massud; Kimberly L Rapp; Meta Cristiano; Mervi A Detorio; Richard A Stanton; Matthew A Bennett; Monique Kierlin-Duncan; Johan Lennerstrand; James H Nettles
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

5.  Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Authors:  Ming-Tain Lai; Meiqing Lu; Peter J Felock; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert M Tynebor; Thomas J Tucker; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

6.  Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Chih-Wei Sheen; Shannon Zelina; Pedro S Argoti Torres; Urvi M Parikh; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

7.  Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Stefan G Sarafianos; Matthew M Schuckmann; Yasuko Sakagami; Masao Matsuoka; Masafumi Takiguchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

8.  Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.

Authors:  Selwyn J Hurwitz; Ghazia Asif; Nancy M Kivel; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

Review 9.  New antiretroviral drugs.

Authors:  Kimberly Hanson; Charles Hicks
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.495

10.  HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.

Authors:  Francesca Esposito; Angela Corona; Enzo Tramontano
Journal:  Mol Biol Int       Date:  2012-06-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.